Back to Report Store Home

Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment

  • Published: Apr-2011
  • Report Code: GBIHC075MR
  • Report Format: pdf

Description

GBI Research’s new report, “Biosimilars Approval Pathways in the US and Europe”, provides insights on biosimilars market revenues and growth till 2016 in the US and Europe. Further, the distribution of revenues across key biosimilar drug classes is provided in the report. The report focuses on the latest developments in the regulatory landscape and the evolving biosimilars approval pathways in the US. Furthermore, the report provides comprehensive insights into the key pricing and reimbursement issues associated with biosimilars in the US. The report also provides the competitive landscape including benchmarking of the leading companies in the biosimilars market. Finally, the report provides an insight into key opportunities and challenges in the future biosimilars market in the US.

Scope

  • The scope of this report includes:

  • Market forecasts and potential for the biosimilars market from 2009 to 2016.

  • Key drivers and restraints that have a significant impact on the biosimilars market.

  • Key latest developments in the regulatory landscape and the evolving biosimilars approval pathways in the US.

  • Information on the pricing and reimbursement of biosimilars.

  • Competitive landscape of the US biosimilars market including benchmarking of the leading companies.

  • Key opportunities and challenges in the future US biosimilars market

Reasons To Buy

  • The report will enhance your decision making capability. It will allow you to

  • Build effective strategies to determine the impact of the evolving biosimilars approval pathway in the US biosimilars market.

  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments poised for strong growth.

  • Determine the most suitable product portfolio by understanding the pricing and reimbursement trends for biosimilars.

  • Device better strategies through the understanding of key drivers and barriers affecting the US biosimilars market.

  • Develop key strategic initiatives by identifying the major opportunities in the future biosimilars market.

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards